Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc(SNDX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$9.45
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SNDX

11/13/2026: SNDX (1-star) is currently NOT-A-BUY. Pass it for now.

Syndax Pharmaceuticals is a clinical-stage biotechnology company that has recently transitioned into a commercial entity with the approval of its lead product for chronic graft-versus-host disease. Its primary strength lies in a specialized, precision-oncology pipeline that addresses significant unmet medical needs in hematology. The investment story centers on the potential market penetration of its commercialized therapy and the future development of its menin inhibitor for acute leukemia. Risks include intense competition from larger pharmaceutical firms, inherent clinical trial uncertainties, and the execution challenges of a new commercial launch. The stock is most suitable for growth-oriented investors interested in the biotechnology sector who can tolerate high volatility.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers exposure to high-growth potential driven by new product launches in the oncology space.
Momentum investorMixed fitMomentum is highly dependent on clinical trial results and regulatory news, requiring a positive trend.
Value investorWeak fitThe company is not currently valued on traditional P/E or yield metrics, making it unsuitable for traditional value strategies.
Dividend investorWeak fitSyndax does not pay a dividend, as it is focused on capital appreciation and reinvestment.
Low-risk investorWeak fitThe inherent risks of biotechnology development make this unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stocks are prone to significant price swings based on clinical data releases.
Valuation riskMedium / highValuations are highly sensitive to clinical outcome assumptions and market adoption expectations.
Competition risk (oncology)HighThe market is crowded with well-funded companies competing for similar patient populations.
Business qualityMediumThe company is transitioning from R&D to commercial, which introduces new execution risks.
Dividend incomeLow / noneThe company does not generate the cash flow required for dividend payments.
Execution riskHighSuccessful drug launch and market access are complex processes prone to challenges.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 850.77M USD
Price to earnings Ratio -
1Y Target Price 35.45
Price to earnings Ratio -
1Y Target Price 35.45
Volume (30-day avg) 3.5M shares
Beta 0.45
52 Weeks Range 9.11 - 25.59
Updated Date 11/14/2026
52 Weeks Range 9.11 - 25.59
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.37

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -7.87%
Avg. Invested days 37
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SNDX receives a 3-star rating, supported by solid company fundamentals, and strong analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
SNDX has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+10.5%) and strong revenue growth (+627.8%) are partially offset by weak cash generation (FCF margin -187.5%), weak profitability (net margin -165.6%), modest insider ownership of 2.85%.

Financial Health Rating

★★★★★
SNDX's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 77.0%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is SNDX's strongest growth driver at +627.8% FY2025 versus FY2024 (strong, 5 stars). By comparison, earnings growth (+10.5%, solid) is also solid, while free-cash-flow growth (-17.6%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 123.5% and approximately 90.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.85% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 10.02%
Kynam Capital Management, LP 8.94%
The Goldman Sachs Group Inc 6.51%
State Street Corp 6.29%
Bank of America Corp 4.49%

Unit Economics (Per $1K Revenue)

★★★★★
SNDX generates approximately $960 of gross profit, $-1,584 of operating income, and $-1,875 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
SNDX has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Product SalesCommercial revenue from the sale of FDA-approved oncology therapies such as Niktimvo.Revenue comes directly from selling specialized cancer drugs to hospitals and healthcare providers.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 668.98M
Price to Sales(TTM) 2.94
Enterprise Value 668.98M
Price to Sales(TTM) 2.94
Enterprise Value to Revenue 2.34
Enterprise Value to EBITDA -105.26
Shares Outstanding 90.03M
Shares Floating 81.19M
Shares Outstanding 90.03M
Shares Floating 81.19M
Percent Insiders 2.85
Percent Institutions 123.47

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.